• Min Kim
  • Stuart Snowden
  • Tommi Suvitaival
  • Ashfaq Ali
  • David J Merkler
  • Tahmina Ahmad
  • Sarah Westwood
  • Alison Baird
  • Petroula Proitsi
  • Alejo Nevado-Holgado
  • Abdul Hye
  • Isabelle Bos
  • Stephanie Vos
  • Rik Vandenberghe
  • Charlotte Teunissen
  • Mara Ten Kate
  • Philip Scheltens
  • Silvy Gabel
  • Karen Meersmans
  • Olivier Blin
  • Jill Richardson
  • Ellen De Roeck
  • Kristel Sleegers
  • Régis Bordet
  • Lorena Rami
  • Petronella Kettunen
  • Magda Tsolaki
  • Frans Verhey
  • Isabel Sala
  • Alberto Lléo
  • Gwendoline Peyratout
  • Mikel Tainta
  • Peter Johannsen
  • Yvonne Freund-Levi
  • Lutz Frölich
  • Valerija Dobricic
  • Giovanni B Frisoni
  • José L Molinuevo
  • Anders Wallin
  • Julius Popp
  • Pablo Martinez-Lage
  • Lars Bertram
  • Frederik Barkhof
  • Nicholas Ashton
  • Kaj Blennow
  • Henrik Zetterberg
  • Johannes Streffer
  • Pieter J Visser
  • Simon Lovestone
  • Cristina Legido-Quigley

INTRODUCTION: A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers.

METHODS: This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis.

RESULTS: Eight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory.

DISCUSSION: PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures.

Original languageEnglish
Pages (from-to)817-827
Number of pages11
JournalAlzheimer's & Dementia
Issue number6
Early online date28 Apr 2019
Publication statusPublished - Jun 2019

    Research areas

  • Alzheimer's disease, Amyloid, Biomarkers, Brain volume measurements, CSF, Cognitive function measurements, Dementia, EMIF-AD, Metabolomics, Tau

ID: 45742374